Publications
Detailed Information
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Robson, Mark E. | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Senkus, Elzbieta | - |
dc.contributor.author | Xu, Binghe | - |
dc.contributor.author | Domchek, Susan M. | - |
dc.contributor.author | Masuda, Norikazu | - |
dc.contributor.author | Delaloge, Suzette | - |
dc.contributor.author | Tung, Nadine | - |
dc.contributor.author | Armstrong, Anne | - |
dc.contributor.author | Dymond, Mike | - |
dc.contributor.author | Fielding, Anitra | - |
dc.contributor.author | Allen, Allison | - |
dc.contributor.author | Conte, Pierfranco | - |
dc.date.accessioned | 2023-05-10T01:21:42Z | - |
dc.date.available | 2023-05-10T01:21:42Z | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.created | 2023-04-11 | - |
dc.date.issued | 2023-05 | - |
dc.identifier.citation | European Journal of Cancer, Vol.184, pp.39-47 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://hdl.handle.net/10371/192242 | - |
dc.description.abstract | Background: In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in pa-tients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). In the final pre-specified analysis (64% maturity), median overall survival (OS) was 19.3 months for olaparib and 17.1 months for TPC (P Z 0.513). Post-hoc extended follow-up, 25.7 months longer than previously reported for OS, is reported. Patients and methods: Patients with gBRCAm, human epidermal growth factor receptor 2 -negative mBC, who had received <2 lines of chemotherapy for metastatic disease, were ran-domised 2:1 to olaparib (300 mg bid) or TPC. During extended follow-up, OS was analysed every 6 months using the stratified log-rank test (overall population) and Cox proportional hazards model (pre-specified subgroups). Results: In the overall population (302 patients; 76.8% maturity), median OS was 19.3 months for olaparib and 17.1 months for TPC (hazard ratio 0.89, 95% confidence interval 0.67-1.18); median follow-up was 18.9 and 15.5 months, respectively. Three-year survival was 27.9% for olaparib versus 21.2% for TPC. With olaparib, 8.8% of patients received study treatment for >3 years versus none with TPC. In first-line mBC, median OS was longer for olaparib than TPC (22.6 versus 14.7 months; hazard ratio 0.55, 95% confidence interval 0.33-0.95) and 3 -year survival was 40.8% for olaparib versus 12.8% for TPC. No new serious adverse events related to olaparib were observed. Conclusions: OS was consistent with previous analyses from OlympiAD. These findings sup-port the possibility of meaningful long-term survival benefit with olaparib, particularly in first-line mBC.(c) 2023 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.title | OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician?s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ejca.2023.01.031 | - |
dc.citation.journaltitle | European Journal of Cancer | - |
dc.identifier.wosid | 000954534300001 | - |
dc.identifier.scopusid | 2-s2.0-85149757127 | - |
dc.citation.endpage | 47 | - |
dc.citation.startpage | 39 | - |
dc.citation.volume | 184 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Germline BRCA mutation | - |
dc.subject.keywordAuthor | Olaparib | - |
dc.subject.keywordAuthor | Overall survival | - |
dc.subject.keywordAuthor | PARP inhibitor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.